73 results
Page 3 of 4
425
EX-99.1
rncdxyhq35tcfde3k jy
7 May 21
Business combination disclosure
7:08am
425
EX-2.1
2vbuj
7 May 21
Business combination disclosure
7:08am
DEF 14A
suhtyl41oepd746z
9 Sep 20
Definitive proxy
4:00pm
PRE 14A
bzkdwv 02331
10 Aug 20
Preliminary proxy
12:00am
10-K
EX-10.3
4q12 7qpp
29 Jun 20
Annual report
4:02pm
10-K
EX-10.2
cgt99lj
29 Jun 20
Annual report
4:02pm
10-K
yh36mrck
29 Jun 20
Annual report
4:02pm
S-3
EX-1.2
h8whicn
29 Jun 20
Shelf registration
12:00am
F-3
EX-4.6
54j ykp79
7 Aug 19
Shelf registration (foreign)
12:00am
6-K
EX-99.1
1zill
14 Feb 19
At Market Issuance Sales Agreement
8:13am
POS AM
t7z4nv
12 Oct 18
Prospectus update (post-effective amendment)
5:05pm
6-K
EX-99.1
ay62 1lzrs
11 Oct 18
Acasti Pharma Announces Closing of $19.1 Million Underwritten Public Offering of Common Shares
7:42am
6-K
EX-99.1
20bn4t
9 Oct 18
Current report (foreign)
5:21pm
424B5
ziubjekasga3wm
5 Oct 18
Prospectus supplement for primary offering
12:00am
6-K
EX-99.1
p3sfeidc6n rir7
4 Oct 18
Acasti Pharma Announces Pricing of $16.6 Million Underwritten Public Offering of Common Shares
11:00am
424B5
96ckerecw8g
3 Oct 18
Prospectus supplement for primary offering
4:51pm
6-K
EX-99.1
27sz72 al2b9jlp3
1 Oct 18
Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest under Debentures
5:00pm
POS AM
ui8b20 n1g9kzz
21 Sep 18
Prospectus update (post-effective amendment)
4:16pm
6-K
EX-99.1
hhu6 u6dwor3
2 Jul 18
Current report (foreign)
5:14pm